COPD – Page 2 – media

The future of lung function tests for COPD

With the global increase of lung diseases such as asthma, severe bronchitis and emphysema, lung function tests are becoming a bigger concern for many people.
- Source: Ddu
- 1,460
- February 7, 2018
COPD Ddu College Spirometry
AstraZeneca’s Three-in-One COPD Inhaler Succeeds in Phase III Trial

AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights. This morning, AstraZeneca revealed Phase III data that shows its experimental three-in-one inhaler PT010 improved lung function in patients.
- Source: Biospace
- 585
- January 29, 2018
Clinical Trials COPD inhaler
Starting new COPD inhaler tied to heart attack risk

People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.
- Source: Reuters
- 523
- January 3, 2018
COPD heart attacks Researches stroke
AZ and ICL link to research respiratory diseases

AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
- Source: pharmatimes
- 548
- December 27, 2017
asthma AstraZeneca COPD Market Views
Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
- Source: Astrazeneca
- 626
- December 8, 2017
AstraZeneca cardiovascular Clinical Trials COPD
Is Mepolizumab an Effective Treatment for Asthma?

Researchers investigated whether mepolizumab is safer and more effective than triple-inhaled treatments for chronic obstructive pulmonary disease.
- Source: medicalnewsbulletin
- 668
- December 4, 2017
asthma COPD mepolizumab
Ddu College-China’s Import and Export Market Report of Respiratory System Drugs

Respiratory system drugs is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will share China’s Import and Export Market Report of Respiratory System Drugs with you.
- Source: Ddu
- 1,315
- November 17, 2017
asthma COPD Ddu College pneumonia respiratory
Rheumatoid arthritis may raise COPD risk

New research suggests that people with rheumatoid arthritis are more likely to develop chronic obstructive pulmonary disease (COPD), which is a group of lung diseases that damage the airways and cause problems with breathing.
- Source: medicalnewstoday
- 546
- October 27, 2017
COPD Researches rheumatoid arthritis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.